source
- Chiesi to acquire KalVista Pharmaceuticals for $1.9 billion in cash dealItalian pharma Chiesi announced it will purchase commercial biotech KalVista Pharmaceuticals. The transaction is valued at about $1.9 billion, with Chiesi paying $27 per share in cash. The acquis…
- AstraZeneca halts several mid- and late-stage trials after efficacy setbacksAstraZeneca announced it has stopped a number of mid- and late-stage clinical trials in its pipeline over recent months. The decision follows disappointing efficacy results in those studies, limit…